Executive Summary

Oct 2019
PROSPECTS
Ibuprofen continues to see higher value growth in 2019

Ibuprofen has gained ground against aspirin and acetaminophen, commonly known as paracetamol, for more than 12 years, and today its per capita consumption in value terms is very high compared to that of the other two categories as its unit price is considerably higher. While all types of analgesics continue to see strong value growth as higher levels of stress at work and increasingly hectic lifestyles fuel demand for pain relief, ibuprofen particularly has been benefitting from this trend.

Sluggish economy leaves little room for significant volume growth, but some improvement is seen

While the economy has improved and somewhat stabilised, it still remains sluggish, so while volume growth of analgesics did improve, it still continued to decline in 2019. Aspirin continued to account for the highest share of volume sales among analgesics over the year, but volume growth of both adult and paediatric versions declined more steeply from 2016 to 2019 than that of ibuprofen, and the volume growth decline of acetaminophen was even steeper over the same period of time.

Agreements with mutual pharmacies boost sales of generics as well as branded analgesics in 2019

Sales of generic drugs have risen in Uruguay thanks to more rational consumer behaviour, with Uruguayans having started to compare prices and opt for the best deals. In line with this trend and in a movement initiated by Laboratorio Espefar, there has been significant development of mutual pharmacies, such as that of Mutual Bancaria, which offers its members discounted or low prices and other benefits.

COMPETITIVE LANDSCAPE
Competition from major players in ibuprofen and aspirin keeps Gramon Bag? from regaining its leading position in 2019

Gramon Bagó de Uruguay was the indisputable leader in analgesics until 2017, when its position fell to second place behind Spefar. Its rank subsequently slid to third, where it now rests, in 2018 when Bayer also surpassed its value share.

Generics outperform brands in analgesics, but agreements with mutual pharmacies promise to make the landscape more competitive

Generic analgesics continue to outperform that of the major brands, but due to the agreements that Bayer and Urufarma have entered into with the mutual pharmacies, which allow them to offer better discounts, their brands are better able to compete against generics and both companies are expected to further benefit from these arrangements over the forecast period.

Chemists/pharmacies account for the highest distribution share, and see the highest growth after that of internet retailing

Multinational brands in analgesics, such as Bayer’s Aspirina and Actron are predominantly sold in chemists/pharmacies and drugstores/parapharmacies in Uruguay. However, a considerable volume is sold in kiosks (other grocery retailers) and through homeshopping.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in Uruguay

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Uruguay with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Uruguay, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Uruguay market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in Uruguay?
  • What are the major brands in Uruguay?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in Uruguay - Category analysis

HEADLINES

PROSPECTS

Ibuprofen continues to see higher value growth in 2019
Sluggish economy leaves little room for significant volume growth, but some improvement is seen
Agreements with mutual pharmacies boost sales of generics as well as branded analgesics in 2019

COMPETITIVE LANDSCAPE

Competition from major players in ibuprofen and aspirin keeps Gramon Bag? from regaining its leading position in 2019
Generics outperform brands in analgesics, but agreements with mutual pharmacies promise to make the landscape more competitive
Chemists/pharmacies account for the highest distribution share, and see the highest growth after that of internet retailing

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in Uruguay - Industry Overview

EXECUTIVE SUMMARY

Improving economy reflected in higher value growth
OTC relatively undeveloped in Uruguay, as health ministry has stricter regulations than in other countries such as neighbouring Argentina
While domestic companies struggle to compete with multinational players, consumer trust and government-backed Mega Pharma support their development
Chemists/pharmacies continues to lose ground to non-store channels and vitamins and dietary specialists
Consumer healthcare is set to see significantly higher growth in most categories over the forecast period

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources